Genmab A/S GMAB
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GMAB is a good fit for your portfolio.
News
-
Correction to Genmab Article
-
Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio
-
AbbVie, Genmab Get Speedy FDA Review of Epkinly in Follicular Lymphoma
-
Genmab, Pfizer Get European Review of Cervical Cancer Drug
-
Pfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval
-
AbbVie, Genmab Get Conditional Europe OK of Tepkinly Lymphoma Drug
-
Airbnb, Tesla stocks rise, Manchester United, Softbank shares fall and other stocks on the move
-
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results
Trading Information
- Previous Close Price
- DKK 1,954.50
- Day Range
- DKK 1,946.00–2,003.00
- 52-Week Range
- DKK 1,825.00–2,939.00
- Bid/Ask
- DKK 1,973.00 / DKK 1,975.00
- Market Cap
- DKK 127.76 Bil
- Volume/Avg
- 124,815 / 126,920
Key Statistics
- Price/Earnings (Normalized)
- 24.02
- Price/Sales
- 7.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.44%
Company Profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 2,204
- Website
- https://www.genmab.com
Competitors
Valuation
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.02 | 15.67 | 14.53 |
Price/Book Value | 3.96 | 0.96 | 2.21 |
Price/Sales | 7.66 | 1.57 | 3.13 |
Price/Cash Flow | 20.98 | 8.14 | 15.52 |
Price/Earnings
GMAB
4502
INCY
Financial Strength
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Quick Ratio | 13.32 | 0.46 | 3.55 |
Current Ratio | 13.34 | 1.06 | 3.75 |
Interest Coverage | 175.00 | 1.93 | 260.45 |
Quick Ratio
GMAB
4502
INCY
Profitability
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | 16.09% | 2.86% | 12.82% |
Return on Equity (Normalized) | 17.97% | 6.13% | 16.79% |
Return on Invested Capital (Normalized) | 15.16% | 4.78% | 14.10% |
Return on Assets
GMAB
4502
INCY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fxjtrqtjp | Gkcz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wflqbyy | Sqkwqfh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nlymfdy | Nhpnpp | $97.8 Bil | |
MRNA
| Moderna Inc | Fdplfxzlw | Ydvcz | $41.3 Bil | |
ARGX
| argenx SE ADR | Tfdhbvx | Wcbm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Stbzsgj | Nfj | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ktxyrthv | Srjwzyz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jbshddcxf | Knrnvb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dbtkrjcmsf | Xccgcgf | $12.5 Bil | |
INCY
| Incyte Corp | Kzcnnxrp | Wvklnw | $11.6 Bil |